Wire · opportunities
Pharmacy Benefit Manager Reaches Settlement with FTC Requiring Changes to Drug ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 20 July 2026 · Fusion42 review
The FTC settled its antitrust case against Caremark (one of three largest PBMs controlling 80% of US prescriptions), requiring structural changes to drug pricing, rebate pass-through to patients, insulin cost caps, and prohibition of hub pharmacies. The settlement estimates $8.5bn in consumer savings over 10 years, with Express Scripts having settled in February 2026 and Optum's case pending.
This Wire brief sits within Fusion42's coverage of Digital Health, and 2 sources have reported it between 20 Jul 2026 and 27 Jul 2026.
◆ ◆ The Wire takeaway
If you supply drugs, pharmacies, or patient assistance services, the rules around PBM rebates and formulary access just changed—and the three largest PBMs have now accepted structural changes that will reshape how they negotiate with you. Rebates that were quietly retained are now flowing to patients; the middleman's ability to lock you out of formularies based on pricing just got constrained.
◆ Coverage
2 sources · first reported 20 Jul 2026 · latest 27 Jul 2026
◆ Related on Wire
◆ Topics